WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018103631) FUSION PROTEIN SLIT2D2(C386S)-HSA AND USE THEREOF IN TREATMENT OF FIBROTIC DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/103631    International Application No.:    PCT/CN2017/114599
Publication Date: 14.06.2018 International Filing Date: 05.12.2017
IPC:
C07K 14/47 (2006.01), C12N 15/12 (2006.01), C07K 19/00 (2006.01), C12N 15/62 (2006.01), A61K 38/17 (2006.01), A61K 47/64 (2017.01), A61P 11/00 (2006.01), A61P 31/00 (2006.01)
Applicants: LI, Huashun [CN/CN]; (CN)
Inventors: LI, Huashun; (CN).
REN, Baoyong; (CN).
LIU, Peng; (CN)
Agent: BEIJING BRIGHT IP AGENCY CO., LTD.; B228, No. 32, Inside the No. 5 Yard, Guangshun North Street Chaoyang District Beijing 100102 (CN)
Priority Data:
201611110752.9 06.12.2016 CN
Title (EN) FUSION PROTEIN SLIT2D2(C386S)-HSA AND USE THEREOF IN TREATMENT OF FIBROTIC DISEASES
(FR) PROTÉINE DE FUSION SLIT2D2(C386S)-HSA ET SON UTILISATION DANS LE TRAITEMENT DE MALADIES FIBREUSES
(ZH) 融合蛋白Slit2D2(C386S)-HSA及其在治疗纤维化疾病中的应用
Abstract: front page image
(EN)The present invention provides a fusion protein of Slit2D2 (C386S) and HSA, and use thereof in the treatment and/or prevention of fibrotic diseases. In the fusion protein, cysteine at position 386 in Slit2D2 domain mutates into serine, which improves stability of the fusion protein. The fusion protein of Slit2D2 (C386S) and HSA prolongs drug metabolic time in vivo while improving the drug stability. The fusion protein of the present invention is effective in prevention and treatment of fibrotic diseases, especially pulmonary fibrosis.
(FR)La présente invention concerne une protéine de fusion de Slit2D2 (C386S) et de HSA, et son utilisation dans le traitement et/ou la prévention de maladies fibreuses. Dans la protéine de fusion, la cystéine en position 386 dans le domaine Slit2D2 mute en sérine, ce qui améliore la stabilité de la protéine de fusion. La protéine de fusion de Slit2D2 (C386S) et de HSA prolonge le temps de métabolisation du médicament in vivo tout en améliorant la stabilité du médicament. La protéine de fusion de la présente invention est efficace dans la prévention et le traitement de maladies fibreuses, en particulier la fibrose pulmonaire.
(ZH)本发明提供了一种Slit2D2(C386S)与HSA的融合蛋白及其在治疗和/或预防纤维化疾病中的应用。所述融合蛋白中Slit2D2结构域中的386位半胱氨酸被突变为丝氨酸,提高了融合蛋白的稳定性;Slit2D2(C386S)与HSA的融合蛋白在提高药物的稳定性的同时延长了药物的体内代谢时间。本发明提供的融合蛋白在纤维化疾病,特别是肺纤维化的预防和治疗方面显示出有效性。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)